Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future immunosuppressive agents in solid-organ transplantation.

Steven Gabardi1, Jeffrey Cerio

  • 1Brigham and Women's Hospital, Boston, MA, USA.

Progress in Transplantation (Aliso Viejo, Calif.)
|July 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection.

Kidney international reports·2023
Same author

A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation.

Transplantation·2022
Same author

Immunosuppression in the Age of Precision Medicine.

Seminars in nephrology·2022
Same author

Implementing a regional standardized BK polyomavirus screening protocol across eleven transplant centres.

Transplant international : official journal of the European Society for Organ Transplantation·2021
Same author

Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.

Reviews in endocrine & metabolic disorders·2021
Same author

Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing.

Transplantation·2021
Same journal

End-of-Life Care of Young Adult Solid Organ Transplant Recipients Compared to Nontransplant Recipients.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same journal

Cost-Savings Realized Using Rabbit Anti-Thymocyte Globulin Ideal Body Weight Dosing for Kidney Transplantation Induction Immunosuppression.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same journal

A Qualitative Study on the Experiences Related to Immunosuppressive Therapy in Liver Transplant Recipients.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same journal

The Impact of Failed Deceased Donor Kidney Graft Longevity on Mortality.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same journal

The Effect of Inhaled Anesthetic Administration on Deceased Organ Donors and Transplant Recipients.

Progress in transplantation (Aliso Viejo, Calif.)·2026
Same journal

A Scoping Review and Practical Approach to Measuring Health Literacy in Solid Organ Transplantation.

Progress in transplantation (Aliso Viejo, Calif.)·2026
See all related articles

New immunosuppressants like mycophenolate sodium, everolimus, and FTY720 show efficacy in solid-organ transplantation. These agents are generally well-tolerated, offering transplant practitioners more immunosuppression options.

Area of Science:

  • Pharmacology and clinical application of novel immunosuppressive agents.

Background:

  • Solid-organ transplantation requires effective immunosuppression to prevent rejection.
  • Emerging immunosuppressive drugs offer new therapeutic avenues.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, efficacy, and safety of mycophenolate sodium, everolimus, and FTY720.
  • To assess their potential role in solid-organ transplantation.

Main Methods:

  • Systematic review of clinical trials and abstracts.
  • Inclusion of English-language studies and published abstracts on mycophenolate sodium, everolimus, and FTY720 in solid-organ transplantation.

Main Results:

  • Mycophenolate sodium, everolimus, and FTY720 demonstrate efficacy in reducing acute rejection.

Related Experiment Videos

  • These agents are generally well-tolerated with manageable adverse events.
  • Common side effects include gastrointestinal and hematologic effects (mycophenolate sodium), hyperlipidemia and renal effects (everolimus), and gastrointestinal issues and bradycardia (FTY720).

    • Conclusions:

    • Mycophenolate sodium is approved in the US and Europe; everolimus is approved in Europe with US FDA submission.
    • FTY720 is in Phase III trials, with future FDA submission anticipated.
    • These agents will expand immunosuppression choices for transplant professionals.